Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 10.3 Form of Earn-out Restricted Stock Unit Agreement Pursuant to the Somalogic, Inc. 2021 Omnibus Incentive Plan
- 10.4 Form of Stock Option Award Agreement Under the Somalogic, Inc. 2021 Omnibus Incentive Plan
- 10.5 Form of Restricted Stock Unit Award Agreement Under the Somalogic, Inc. 2021 Omnibus Incentive Plan
- 10.6 Form of Restricted Stock Award Agreement Under the Somalogic, Inc. 2021 Omnibus Incentive Plan
- 10.7 Somalogic, Inc. 2009 Equity Incentive Plan
- 10.33 Master Collaboration Agreement
- 10.34 Amended and Restated Master Somascan Discovery Services Agreement, Dated October 13, 2020, Between Somalogic, Inc. and Amgen Inc
- 23.1 Consent of Withumsmith+brown, PC
- 23.2 Consent of Ernst & Young LLP
- 99.4 Consent of Houlihan Lokey Capital, Inc
Associated filings
- 13 Aug 21 EFFECT Notice of effectiveness
- 12 Aug 21 424B3 Prospectus supplement
- 5 Aug 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 22 Jul 21 S-4/A Registration of securities issued in business combination transactions (amended)
-
25 Jun 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 14 May 21 S-4 Registration of securities issued in business combination transactions
SLGCW similar filings
Filing view
External links
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption "Experts" and to the use of our report dated May 14, 2021, with respect to the consolidated financial statements of SomaLogic, Inc. included in the Proxy Statement of CM Life Sciences II Inc. that is made a part of Amendment No. 1 to the Registration Statement (Form S-4 No. 333-256127) and related Prospectus of CM Life Sciences II Inc. for the registration of up to 130,000,000 shares of its common stock.
/s/ Ernst & Young LLP
Denver, Colorado
June 25, 2021